Palos-Paz F, Perez-Guerra O, Cameselle-Teijeiro J, Rueda-Chimeno C, Barreiro-Morandeira F, Lado-Abeal J, Araujo Vilar D, Argueso R, Barca O, Botana M, Cabezas-Agrícola J M, Catalina P, Dominguez Gerpe L, Fernandez T, Mato A, Nuño A, Penin M, Victoria B
Unidade de Enfermedades Tiroideas e Metabólicas (UETeM), Complexo Hospitalario Universitary de Santiago (CHUS), University of Santiago de Compostela, Santiago de Compostela, 15705, Spain.
Eur J Endocrinol. 2008 Nov;159(5):623-31. doi: 10.1530/EJE-08-0313. Epub 2008 Aug 11.
Toxic thyroid adenoma (TA) is a common cause of hyperthyroidism. Mutations in the TSH receptor (TSHR) gene, and less frequently in the adenylate cyclase-stimulating G alpha protein (GNAS) gene, are well established causes of TA in Europe. However, genetic causes of TA remain unknown in a small percentage of cases. We report the first study to investigate mutations in TSHR, GNAS, protein kinase, cAMP-dependent, regulatory, type I alpha (PRKAR1A) and RAS genes, in a large series of TA from Galicia, an iodine-deficient region in NW Spain.
Eighty-five TA samples were obtained surgically from 77 hyperthyroid patients, operated on for treatment of non-autoimmune toxic nodular goitre. After DNA extraction, all coding exons of TSHR, GNAS and PRKAR1A genes, and exons 2 and 3 of HRAS, KRAS and NRAS were amplified by PCR and sequenced. Previously unreported mutants were cloned in expression vectors and their basal constitutive activities were determined by quantification of cAMP response element (CRE)-luciferase activity in CO7 cells transfected with wild-type and mutant plasmids.
TSHR gene mutations were found in 52 (61.2%) samples, GNAS gene mutations in 4 (4.71%) samples and no PRKAR1A or RAS mutations were found. Only three previously unreported mutations were found, two affecting the TSHR, A623F and I635V, and one affecting the G-protein alpha-subunit (Gsalpha), L203P. All mutant proteins showed higher CRE-luciferase activity than their wild-type counterparts.
TA in a hyperthyroid population living in Galicia, a Spanish iodine-deficient region, harbours elevated frequencies of TSHR and GNAS mutations activating the cAMP pathway. However, the genetic cause of TA was undetermined in 34% of the TA samples.
毒性甲状腺腺瘤(TA)是甲状腺功能亢进症的常见病因。在欧洲,促甲状腺激素受体(TSHR)基因突变以及腺苷酸环化酶刺激型Gα蛋白(GNAS)基因较少见的突变是TA的明确病因。然而,在一小部分病例中,TA的遗传病因仍不明确。我们报告了第一项针对来自西班牙西北部碘缺乏地区加利西亚的大量TA病例,研究TSHR、GNAS、蛋白激酶、cAMP依赖性、调节性、I型α(PRKAR1A)和RAS基因的突变情况的研究。
从77例接受手术治疗非自身免疫性毒性结节性甲状腺肿的甲状腺功能亢进患者中,手术获取85个TA样本。提取DNA后,通过聚合酶链反应(PCR)扩增TSHR、GNAS和PRKAR1A基因的所有编码外显子,以及HRAS、KRAS和NRAS的外显子2和3,并进行测序。将先前未报道的突变体克隆到表达载体中,并通过定量转染野生型和突变体质粒的CO7细胞中cAMP反应元件(CRE)-荧光素酶活性来测定其基础组成活性。
在52个(61.2%)样本中发现TSHR基因突变,在4个(4.71%)样本中发现GNAS基因突变,未发现PRKAR1A或RAS基因突变。仅发现3个先前未报道的突变,2个影响TSHR,即A623F和I635V,1个影响G蛋白α亚基(Gsα),即L203P。所有突变蛋白的CRE-荧光素酶活性均高于其野生型对应物。
生活在西班牙碘缺乏地区加利西亚的甲状腺功能亢进人群中的TA,TSHR和GNAS激活cAMP途径的突变频率较高。然而,在34%的TA样本中,TA的遗传病因仍未确定。